<DOC>
	<DOCNO>NCT02659020</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy two anti-cancer drug ( gemcitabine docetaxel ) without study drug know olaratumab participant advance soft tissue sarcoma ( STS ) STS spread another part ( ) body .</brief_summary>
	<brief_title>A Study Olaratumab ( LY3012207 ) Participants With Advanced Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>The participant may 2 prior line systemic therapy ( neoadjuvant adjuvant therapy consider prior line therapy ) advance metastatic disease suitable receive gemcitabine docetaxel therapy . All previous therapy must complete â‰¥ 4 week ( 28 day ) prior enrollment ( Phase 1b ) / randomization ( Phase 2 ) . Availability tumor tissue mandatory study eligibility . The participant must consent provide archive formalinfixed paraffinembedded tumor tissue subject pretreatment rebiopsy primary metastatic tumor tissue future central pathology review translational research ( archived tissue unavailable ) . The participant adequate hematologic , organ , coagulation function within 2 week ( 14 day ) prior enrollment ( Phase 1b ) randomization ( Phase 2 ) . The participant diagnose gastrointestinal stromal tumor ( GIST ) Kaposi sarcoma . The participant active central nervous system ( CNS ) leptomeningeal metastasis ( brain metastasis ) time enrollment ( Phase 1b ) randomization ( Phase 2 ) . Participants history CNS metastasis previously treat curative intent ( example , stereotactic radiation surgery ) progress followup imaging , asymptomatic least 60 day , receive systemic corticosteroid or/anticonvulsants , eligible . Participants sign symptom neurological compromise appropriate radiographic imaging perform enrollment ( Phase 1b ) /randomization ( Phase 2 ) rule brain metastasis . The participant receive prior treatment gemcitabine , docetaxel , and/or olaratumab . Note : Participants previously enrol I5BMCJGDJ ( NCT02451943 ) blind study olaratumab eligible participate trial . The participant electively plan require major surgery course study . Females pregnant breastfeeding . The participant active fungal , bacterial , and/or know viral infection include human immunodeficiency virus ( HIV ) viral ( A , B , C ) hepatitis ( screen require ) .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>